PMID- 34748077
OWN - NLM
STAT- MEDLINE
DCOM- 20220120
LR  - 20220120
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 101
IP  - 2
DP  - 2022 Feb
TI  - Outcomes of patients with multiple myeloma harboring chromosome 1q 
      gain/amplification in the era of modern therapy.
PG  - 369-378
LID - 10.1007/s00277-021-04704-8 [doi]
AB  - Chromosome 1q gain/amplification (1q +) has been reported to be associated with 
      inferior outcomes in multiple myeloma (MM) patients. Big therapeutic advances 
      have shifted the treatment landscape by introducing monoclonal antibodies. There 
      is a relative lack of data on outcomes in patients harboring this alteration in 
      the era of monoclonal antibodies. Baseline characteristics and therapy-related 
      data from newly diagnosed MM patients harboring 1q + detected by fluorescence in 
      situ hybridization (FISH) were collected in a single institution. Among 34 
      identified subjects, the presence of elevated LDH was found to be associated with 
      shorter overall survival (OS), and increased bone marrow plasma cell percentage 
      (>/= 60%) was associated with worse progression-free survival (PFS). 1q + copy 
      number more than three was associated with both shorter OS and PFS. Additionally, 
      the administration of lenalidomide was associated with superior OS. The use of 
      autologous stem cell transplantation, bortezomib, or daratumumab, was found to 
      have no prognostic benefits in our sample. Lenalidomide may be an optimal 
      therapeutic choice for this population, and future larger studies are warranted 
      to confirm this benefit and further investigate the role of monoclonal 
      antibodies in this subpopulation.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Hu, Xiao
AU  - Hu X
AUID- ORCID: 0000-0001-9036-8455
AD  - Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, 02111, USA.
FAU - Wu, Cherng-Horng
AU  - Wu CH
AD  - Department of Medicine, Tufts Medical Center, Boston, MA, 02111, USA.
FAU - Cowan, Janet M
AU  - Cowan JM
AD  - Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, 
      MA, 02111, USA.
FAU - Comenzo, Raymond L
AU  - Comenzo RL
AUID- ORCID: 0000-0002-6255-5824
AD  - Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, 02111, USA.
AD  - Tufts Medical Center, The John Conant Davis Myeloma and Amyloid Program, Boston, 
      MA, 02111, USA.
FAU - Varga, Cindy
AU  - Varga C
AUID- ORCID: 0000-0003-4882-5581
AD  - Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, 02111, USA. 
      cind.varga@gmail.com.
AD  - Tufts Medical Center, The John Conant Davis Myeloma and Amyloid Program, Boston, 
      MA, 02111, USA. cind.varga@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20211108
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Aged
MH  - *Chromosome Duplication
MH  - *Chromosomes, Human, Pair 1
MH  - Disease Management
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/epidemiology/*genetics/therapy
MH  - Retrospective Studies
MH  - Survival Analysis
OTO - NOTNLM
OT  - Chromosome 1q gain/amplification
OT  - Daratumumab
OT  - Lenalidomide
OT  - Multiple myeloma
OT  - Prognosis
EDAT- 2021/11/09 06:00
MHDA- 2022/01/21 06:00
CRDT- 2021/11/08 12:26
PHST- 2021/06/07 00:00 [received]
PHST- 2021/10/14 00:00 [accepted]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2022/01/21 06:00 [medline]
PHST- 2021/11/08 12:26 [entrez]
AID - 10.1007/s00277-021-04704-8 [pii]
AID - 10.1007/s00277-021-04704-8 [doi]
PST - ppublish
SO  - Ann Hematol. 2022 Feb;101(2):369-378. doi: 10.1007/s00277-021-04704-8. Epub 2021 
      Nov 8.